1. [Cytomegalovirus pneumopathies in pediatric intensive care units]
- Author
-
Damay, M., Mathé, J. C., Couprie, C., Chevalier, J. Y., Sardet, A., Garbarg-Chenon, A., Boccon-Gibod, L., Costil, J., Perron, Nicolas, and Université Pierre et Marie Curie - Paris 6 (UPMC)
- Subjects
Male ,[CHIM.ORGA]Chemical Sciences/Organic chemistry ,Pneumonia, Viral ,virus diseases ,Infant ,[CHIM.ORGA] Chemical Sciences/Organic chemistry ,Intensive Care Units, Pediatric ,Cohort Studies ,Child, Preschool ,Cytomegalovirus Infections ,Humans ,Female ,Child ,Ganciclovir - Abstract
International audience; BACKGROUND: Cytomegalovirus (CMV) infection can result in major complications in immunocompromised infants and children. CMV pneumonia may be difficult to diagnose and the true pathogenic role of the virus in the disease is not always clear. This report describes a cohort of 20 children who suffered from CMV pneumonia. POPULATIONS AND METHODS: Twenty children aged 1 month to 11 years 10 months were admitted to our intensive care unit between 1981 and 1990 because of pneumonia with evidence of CMV infection. They were classified into three groups: group I (cases 1-10) with hemopathy or cancer, group II (cases 11-14) with AIDS, and group III (cases 15-20): non immunodeficient or immunosuppressed children. CMV infection was diagnosed after isolation of CMV from bronchoalveolar lavage (BAL) fluid (15 patients), lung biopsy revealing intranuclear inclusions or CMV antigens, or CMV-positive cultures (four patients), CMV-positive urine cultures (one patient). RESULTS: Clinical manifestations and X-rays findings were unspecific; interstitial pneumonia was found only in immunodeficient patients. CMV pneumonia was diagnosed only in two patients on post mortem examination. Concomitant pneumocystis carinii was found on BAL in two patients (group I) and two others (group II). Thirteen patients required ventilation. Eleven patients were given ganciclovir for 2 or 3 weeks; one of them was given a single dose. This treatment was well tolerated. Mortality was 90% in group I, 100% in group II and 33% in group III. CONCLUSION: Ganciclovir did not appear to benefit the immunocompromised patients with CMV pneumonia. Future treatment should include hyperimmune CMV immunoglobulins plus ganciclovir. Careful hand washing is important for all those caring for these patients to prevent contamination as is the use of CMV-negative blood products.
- Published
- 1994